EDITAS MEDICINE, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
EDITAS MEDICINE, INC. (EDIT) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$33.58 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-09
- EDITAS MEDICINE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$33.58M.
- EDITAS MEDICINE, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$49.74M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$33.58M 10-K · filed 2026-03-09 |
| 2024-12-31 | -$49.74M 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |